Table 4 Risk of mortality associated with use of cardiovascular treatment drugs in the AF cohort
From: Risk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillation
Cases | Controls | Odds Ratio* | |||
|---|---|---|---|---|---|
n = 234 | (%) | n = 801 | (%) | (95% CI) | |
Diuretics | |||||
Non use | 46 | (19.7) | 237 | (29.6) | 1 |
Current use | 135 | (57.7) | 419 | (52.3) | 1.1 (0.6–1.7) |
Past use | 53 | (22.6) | 145 | (18.1) | 1.1 (0.6–1.9) |
Beta Blockers | |||||
Non use | 169 | (72.2) | 561 | (70.0) | 1 |
Current use | 13 | (5.6) | 87 | (10.9) | 0.8 (0.4–1.6) |
Past use | 52 | (22.2) | 153 | (19.1) | 1.0 (0.6–1.6) |
ACE inhibitors | |||||
Non use | 137 | (58.5) | 524 | (65.4) | 1 |
Current use | 70 | (29.9) | 208 | (26.0) | 0.8 (0.5–1.3) |
Past use | 27 | (11.5) | 69 | (8.6) | 1.0 (0.5–1.8) |
Calcium Channel | |||||
Blockers | |||||
Non use | 165 | (70.5) | 560 | (69.9) | 1 |
Current | 18 | (7.7) | 125 | (15.6) | 0.4 (0.2–0.7) |
Past use | 51 | (21.8) | 116 | (14.5) | 1.2 (0.7–1.8) |
Digoxin | |||||
Non use | 51 | (21.8) | 191 | (23.8) | 1 |
Current | 143 | (61.1) | 496 | (61.9) | 0.9 (0.6–1.4) |
Past use | 40 | (17.1) | 114 | (14.2) | 1.0 (0.5–1.7) |
Amiodarone † | |||||
Non use | 212 | (90.6) | 726 | (90.6) | 1 |
Current | 14 | (6.0) | 44 | (5.5) | 1.3 (0.6–2.8) |
Past use | 8 | (3.4) | 31 | (3.9) | 0.8 (0.3–2.2) |
Warfarin | |||||
Non use | 174 | (74.4) | 503 | (62.8) | 1 |
Current | 37 | (15.8) | 226 | (28.2) | 0.5 (0.3–0.8) |
Past use | 23 | (9.8) | 72 | (9.0) | 1.0 (0.5–1.8) |
Aspirin | |||||
Non use | 109 | (46.6) | 407 | (50.8) | 1 |
Current | 72 | (30.8) | 239 | (29.8) | 0.6 (0.4–0.9) |
Past use | 53 | (22.6) | 155 | (19.4) | 0.8 (0.5–1.2) |